Northern Trust’s Argos Therapeutics, Inc. ARGS Stock Holding History

Northern Trust’s Portfolio ARGS Stock Details ARGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-2,162	Closed	-$6K	–	4347
2017 Q4	$6K	Hold	2,162	–	–	﹤0.01%	4210
2017 Q3	$8K	Hold	2,162	–	–	﹤0.01%	4212
2017 Q2	$16K	Sell	2,162 -5,469	-72%	-$46.6K	﹤0.01%	4198
2017 Q1	$69K	Buy	7,631 +315	+4%	+$19.9K	﹤0.01%	4020
2016 Q4	$717K	Buy	7,316 +427	+6%	+$39.9K	﹤0.01%	3437
2016 Q3	$685K	Buy	6,889 +1,084	+19%	+$113K	﹤0.01%	3438
2016 Q2	$712K	Buy	5,805 +5,246	+938%	+$700K	﹤0.01%	3430
2016 Q1	$71K	Hold	559	–	–	﹤0.01%	3970
2015 Q4	$26K	Hold	559	–	–	﹤0.01%	4146
2015 Q3	$54K	Buy	+559	New	+$66.2K	﹤0.01%	4055
2015 Q2	–	Sell	-527	Closed	-$94K	–	4388
2015 Q1	$94K	Sell	527 -57	-10%	-$9.92K	﹤0.01%	4053
2014 Q4	$117K	Buy	+584	New	+$105K	﹤0.01%	3952
2014 Q3	–	Sell	-2,001	Closed	-$322K	–	4430
2014 Q2	$322K	Buy	2,001 +1,139	+132%	+$188K	﹤0.01%	3723
2014 Q1	$172K	Buy	+862	New	+$172K	﹤0.01%	3824

Other funds holding ARGS

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Northern Trust's ARGS Position: Q1 2018 in Review

Northern Trust sold out of Argos Therapeutics, Inc. (ARGS) in Q1 2018, closing a stake of 2,162 shares — an estimated $6K sold.

Northern Trust first reported a position in ARGS in Q1 2014 and held it in 14 quarters. The position peaked at $717K in Q4 2016. 16 funds tracked by Wall St. Rank hold ARGS as of Q1 2018.

Northern Trust reported no remaining Argos Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Northern Trust sold 2,162 Argos Therapeutics, Inc. shares in Q1 2018, an estimated $6K.
Northern Trust first reported a position in Argos Therapeutics, Inc. in Q1 2014 and held it in 14 quarters.
Northern Trust's Argos Therapeutics, Inc. position peaked at $717K in Q4 2016.
16 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q1 2018.

Based on Northern Trust's 13F filing for Q1 2018, filed 9 May 2018.